NEW YORK / Apr 22, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31, 2024 after the markets close on Wednesday, May 8, 2024. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day.
Conference call and webcast details:
Wednesday, May 8, 2024
5:00 p.m. ET
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13745526
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$4.25 |
Daily Change: | 0.03 0.71 |
Daily Volume: | 258,251 |
Market Cap: | US$431.500M |
December 18, 2024 December 10, 2024 December 04, 2024 November 26, 2024 November 07, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load